protein geranylgeranyltransferase type I subunit beta pseudogene 2Genealiases: []
Q-omics provides the consensus-scored PGGT1BP2 profile across patient tissues and cancer cell-line models. PGGT1BP2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PGGT1BP2 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, PGGT1BP2 RNA expression shows 6,476 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, LUAD, and STAD as cancer lineages where PGGT1BP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PGGT1BP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PGGT1BP2 survival associations across molecular data types. PGGT1BP2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PGGT1BP2 RNA expression–survival associations across cancer types. High PGGT1BP2 expression shows unfavorable associations in BRCA, KIRC and OV, but favorable associations in ACC, READ and CESC. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for PGGT1BP2 RNA expression.
This table summarizes PGGT1BP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PGGT1BP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PGGT1BP2 shows lower tumor expression in KIRP and KICH and higher tumor expression in LUAD. The LUAD box plot shows higher PGGT1BP2 RNA expression in tumor versus normal tissue (log2 FC = +0.220, t-test p < 0.001).
This table shows molecular features associated with PGGT1BP2 in patient tissues and cancer cell lines. In patient samples, PGGT1BP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
